Y Jaillais, M Hothorn, Y Belkhadir… - Genes & …, 2011 - genesdev.cshlp.org Receptor tyrosine kinases control many critical processes in metazoans, but these enzymes appear to be absent in plants. Recently, two Arabidopsis receptor kinases—BRASSINOSTEROID INSENSITIVE 1 (BRI1) and BRI1-ASSOCIATED KINASE1 (BAK1), the receptor and ... Cited by 7 - Related articles - All 5 versions
M Sela, Y Bogin, D Beach, T Oellerich… - The EMBO …, 2011 - nature.com Cooperatively assembled signalling complexes, nucleated by adaptor proteins, integrate information from surface receptors to determine cellular outcomes. In T and mast cells, antigen receptor signalling is nucleated by three adaptors: SLP-76, Gads and LAT. Three well-characterized SLP-76 ... All 3 versions
S O'Sullivan, JM Lin, M Watson, K Callon… - Bone, 2011 - Elsevier Nilotinib is a tyrosine kinase inhibitor (TKI) developed to manage imatinib-resistance in patients with chronic myeloid leukaemia (CML). It inhibits similar molecular targets to imatinib, but is a significantly more potent inhibitor of Bcr-Abl. Nilotinib exhibits off-target effects in other ... Cited by 1 - All 3 versions
OA Guryanova, Q Wu, L Cheng, JD Lathia… - Cancer Cell, 2011 - Elsevier Glioblastomas display cellular hierarchies containing tumor-propagating glioblastoma stem cells (GSCs). STAT3 is a critical signaling node in GSC maintenance but molecular mechanisms underlying STAT3 activation in GSCs are poorly defined. Here we demonstrate that the bone marrow ... Cited by 2 - All 2 versions
JE Chaft, GR Oxnard, CS Sima, VA Miller… - Clinical Cancer …, 2011 - AACR ... resistance to erlotinib or gefitinib -mutant lung cancer and acquired EGFR patients with Disease flare after tyrosine kinase inhibitor discontinuation in ... Page 2. Disease flare after tyrosine kinase inhibitor discontinuation in patients with ...
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
